Simplex Trading’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-18,610
| Closed | -$483 | – | 8944 |
|
|
2025
Q4 | $483 | Buy |
18,610
+6,186
| +50% | +$840 | ﹤0.01% | 8162 |
|
|
2025
Q3 | $1K | Buy |
+12,424
| New | +$1.71K | ﹤0.01% | 8755 |
|
|
2024
Q4 | – | Sell |
-1,052
| Closed | -$767 | – | 8378 |
|
|
2024
Q3 | $0 | Buy |
+1,052
| New | +$1.19K | ﹤0.01% | 8345 |
|
|
2024
Q1 | – | Sell |
-300
| Closed | -$362 | – | 8723 |
|
|
2023
Q4 | $0 | Buy |
+300
| New | +$169 | ﹤0.01% | 8664 |
|
|
2023
Q3 | – | Sell |
-9,408
| Closed | -$7.89K | – | 8531 |
|
|
2023
Q2 | $8K | Sell |
9,408
-3,681
| -28% | -$4.39K | ﹤0.01% | 7551 |
|
|
2023
Q1 | $14K | Buy |
13,089
+7,985
| +156% | +$12.4K | ﹤0.01% | 7228 |
|
|
2022
Q4 | $7K | Buy |
5,104
+3,777
| +285% | +$6.12K | ﹤0.01% | 7789 |
|
|
2022
Q3 | $1K | Sell |
1,327
-12,230
| -90% | -$22.5K | ﹤0.01% | 9470 |
|
|
2022
Q2 | $23K | Buy |
13,557
+9,145
| +207% | +$15.7K | ﹤0.01% | 7427 |
|
|
2022
Q1 | $9K | Sell |
4,412
-5,071
| -53% | -$13.7K | ﹤0.01% | 8934 |
|
|
2021
Q4 | $35K | Sell |
9,483
-3,882
| -29% | -$17.7K | ﹤0.01% | 7684 |
|
|
2021
Q3 | $58K | Sell |
13,365
-9,315
| -41% | -$41.8K | ﹤0.01% | 7330 |
|
|
2021
Q2 | $96K | Sell |
22,680
-11,594
| -34% | -$56.3K | ﹤0.01% | 6775 |
|
|
2021
Q1 | $181K | Buy |
34,274
+7,868
| +30% | +$45K | ﹤0.01% | 4892 |
|
|
2020
Q4 | $142K | Buy |
+26,406
| New | +$143K | ﹤0.01% | 5049 |
|
|
2020
Q3 | – | Sell |
-1,714
| Closed | -$15K | – | 7686 |
|
|
2020
Q2 | $17K | Sell |
1,714
-1,436
| -46% | -$9.02K | ﹤0.01% | 6322 |
|
|
2020
Q1 | $8K | Buy |
+3,150
| New | +$10.5K | ﹤0.01% | 6583 |
|
|
2019
Q4 | – | Sell |
-65
| Closed | – | – | 7195 |
|
|
2019
Q3 | $0 | Sell |
65
-1,340
| -95% | -$3.13K | ﹤0.01% | 7160 |
|
|
2019
Q2 | $5K | Sell |
1,405
-707
| -33% | -$2.88K | ﹤0.01% | 6428 |
|
|
2019
Q1 | $9K | Buy |
+2,112
| New | +$9.83K | ﹤0.01% | 6183 |
|
|
2018
Q4 | – | Sell |
-8,620
| Closed | -$63.6K | – | 6894 |
|
|
2018
Q3 | $116K | Buy |
8,620
+412
| +5% | +$4.32K | ﹤0.01% | 4277 |
|
|
2018
Q2 | $97K | Buy |
8,208
+6,086
| +287% | +$75.9K | ﹤0.01% | 4324 |
|
|
2018
Q1 | $23K | Buy |
+2,122
| New | +$18.6K | ﹤0.01% | 3208 |
|
|
2017
Q4 | – | Sell |
-87
| Closed | – | – | 5887 |
|
|
2017
Q3 | $0 | Sell |
87
-222
| -72% | -$1.39K | ﹤0.01% | 5792 |
|
|
2017
Q2 | $1K | Buy |
+309
| New | +$1.61K | ﹤0.01% | 5492 |
|
Other funds holding ADAP
Simplex Trading's ADAP Position: Q1 2026 in Review
Simplex Trading sold out of Adaptimmune Therapeutics (ADAP) in Q1 2026, closing a stake of 18,610 shares — an estimated $483 sold.
Simplex Trading first reported a position in ADAP in Q2 2017 and held it in 25 quarters. The position peaked at $181K in Q1 2021. 1 fund tracked by Wall St. Rank holds ADAP as of Q1 2026.
- Simplex Trading reported no remaining Adaptimmune Therapeutics position as of Q1 2026 after selling out during the quarter.
- Simplex Trading sold 18,610 Adaptimmune Therapeutics shares in Q1 2026, an estimated $483.
- Simplex Trading first reported a position in Adaptimmune Therapeutics in Q2 2017 and held it in 25 quarters.
- Simplex Trading's Adaptimmune Therapeutics position peaked at $181K in Q1 2021.
- 1 fund tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2026.
Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.